Lytix Biopharma’s licensing partner Verrica Pharmaceuticals Inc. reports interim Phase II data with LTX-315
Promising clinical results showed clearance of basal cell carcinoma lesions in 4 of 6 patients
Potential as non-surgical therapeutic approach for basal cell carcinoma, the most common form of cancer in the US
Oslo, 11 August 2023. Lytix Biopharma – Lytix Biopharma AS (“Lytix”) (Euronext Growth Oslo: LYTIX), a clinical-stage biotech using host-defense peptide derived molecules to kill cancer cells and kick start the immune system, announces that its licensing partner Verrica Pharmaceuticals Inc (“Verrica”) has reported lesion clearance data from Part 1 of an ongoing Phase II study of VP-315 (formerly known as LTX-315) for the treatment of basal cell carcinoma (BCC). Verrica has an exclusive worldwide license agreement with Lytix to develop and commercialize LTX-315 for dermatologic oncology indications and is currently performing a clinical Phase II study in patients with BCC.
